



Recent Vaccine Development for Emerging Infectious Diseases

Guest Editors:

Prof. Dr. Yasir Waheed

Office of Research, Innovation
and Commercialization (ORIC),
Shaheed Zulfiqar Ali Bhutto
Medical University (SZABMU),
Islamabad 44000, Pakistan

Dr. Khalid Muhammad

Department of Biology, College
of Science, United Arab Emirates
University, Al Ain, United Arab
Emirates

Deadline for manuscript
submissions:

31 August 2024

Message from the Guest Editors

Emerging infectious diseases are infections that have recently appeared within a population or those whose incidence or geographic range is rapidly increasing or threatens to increase in the near future. Emerging infections can be caused by previously unknown infectious agents, known agents that have spread to new geographic locations or new populations, or the re-emergence of agents whose incidence of disease had significantly declined in the past, but whose incidence has reappeared.

The world is continuously facing the threats of emerging infectious diseases. COVID-19 has affected over 200 countries of the world and severely affected the healthcare and financial systems of both developed and developing countries. Monkeypox infections are also being reported from different countries and there has been a recent increase in cases of Ebola virus in Uganda. There is a strong need to understand the threats of emerging infectious diseases and have an effective global plan to develop vaccines for these diseases.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPLus / SciFinder**, and **other databases**.

Journal Rank: JCR - Q1 (*Immunology*) / CiteScore - Q1 (*Pharmacology (medical)*)

Contact Us

Vaccines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com